Compendium of Cancer Genome Aberrations

Changes

HAEM5:Volunteer Assignments and Opportunities (view source)

Revision as of 20:35, 17 December 2023

554 bytes added ,  20:35, 17 December 2023
no edit summary
Line 5: Line 5:  
!Correlated Prior Disease Name (4th Edition)
 
!Correlated Prior Disease Name (4th Edition)
 
!Correlated Prior Author (4th Edition)
 
!Correlated Prior Author (4th Edition)
 +
!Content Status (4th Edition)(Pending or Complete)
 
!Date of Last Editor Review (4th Edition)
 
!Date of Last Editor Review (4th Edition)
 
!Notes (4th Edition)
 
!Notes (4th Edition)
Line 13: Line 14:  
|
 
|
 
----<br />
 
----<br />
 +
|
 
|
 
|
 
|
 
|
Line 26: Line 28:  
|-
 
|-
 
|Clonal haematopoiesis||Disease|| || || || || ||Fabiola Quintero-Rivera (FQR)|| ||
 
|Clonal haematopoiesis||Disease|| || || || || ||Fabiola Quintero-Rivera (FQR)|| ||
 +
|NEW DISEASE
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
−
|
  −
|
   
|-
 
|-
 
|Clonal cytopenias of undetermined significance||Disease|| || || || || ||FQR|| ||
 
|Clonal cytopenias of undetermined significance||Disease|| || || || || ||FQR|| ||
 +
|NEW DISEASE
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
−
|
  −
|
   
|-
 
|-
 
|Chronic myeloid leukaemia||Disease|| || || || || ||FQR|| ||
 
|Chronic myeloid leukaemia||Disease|| || || || || ||FQR|| ||
 
|Chronic Myeloid Leukemia (CML), BCR-ABL1 Positive
 
|Chronic Myeloid Leukemia (CML), BCR-ABL1 Positive
 
|Jack Reid, MD (University of California, Irvine)  Mark Evans, MD (University of California, Irvine)  Fabiola Quintero-Rivera, MD (University of California, Irvine)
 
|Jack Reid, MD (University of California, Irvine)  Mark Evans, MD (University of California, Irvine)  Fabiola Quintero-Rivera, MD (University of California, Irvine)
 +
|
 
|Date page was created
 
|Date page was created
 
|
 
|
Line 46: Line 51:  
|Chronic Neutrophilic Leukemia (CNL)
 
|Chronic Neutrophilic Leukemia (CNL)
 
|Anamaria Munteanu, MD, Ph.D**, Harbor-UCLA Medical Center, Joseph J. Merlo Jr, MD. Ph.D**, Ashion Analytics, Fabiola Quintero-Rivera, University of California Irvine  <nowiki>**</nowiki>contributed equally
 
|Anamaria Munteanu, MD, Ph.D**, Harbor-UCLA Medical Center, Joseph J. Merlo Jr, MD. Ph.D**, Ashion Analytics, Fabiola Quintero-Rivera, University of California Irvine  <nowiki>**</nowiki>contributed equally
 +
|
 
|Date page was created
 
|Date page was created
 
|
 
|
Line 52: Line 58:  
|Chronic Eosinophilic Leukemia, Not Otherwise Specified
 
|Chronic Eosinophilic Leukemia, Not Otherwise Specified
 
|Chelsea D. Kramish; Daynna J.Wolff
 
|Chelsea D. Kramish; Daynna J.Wolff
 +
|
 
|
 
|
 
|
 
|
Line 58: Line 65:  
|Polycythemia Vera (PV)
 
|Polycythemia Vera (PV)
 
|Gokce A. Toruner, MD, PhD  UT MD Anderson Cancer Center
 
|Gokce A. Toruner, MD, PhD  UT MD Anderson Cancer Center
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Essential thrombocythaemia||Disease||Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN|| || || || ||FQR|| ||
+
|Essential thrombocythaemia||Disease|| || || || || ||FQR|| ||
 
|Essential Thrombocythemia (ET)
 
|Essential Thrombocythemia (ET)
 +
|Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN
 
|
 
|
 
|
 
|
Line 68: Line 77:  
|-
 
|-
 
|Primary myelofibrosis||Disease||T. Niroshi Senaratne, UCLA|| || || || ||FQR|| ||
 
|Primary myelofibrosis||Disease||T. Niroshi Senaratne, UCLA|| || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
Line 74: Line 84:  
|-
 
|-
 
|Juvenile myelomonocytic leukaemia||Disease|| '''Sarah Rapisardo, PhD, FACMG''' |Assistant Professor, Pathology  Associate Director | Division of Molecular Pathology, Genetics and Genomics  Duke University Health System Clinical Laboratories|| || || || ||FQR|| ||
 
|Juvenile myelomonocytic leukaemia||Disease|| '''Sarah Rapisardo, PhD, FACMG''' |Assistant Professor, Pathology  Associate Director | Division of Molecular Pathology, Genetics and Genomics  Duke University Health System Clinical Laboratories|| || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
Line 80: Line 91:  
|-
 
|-
 
|Myeloproliferative neoplasm, NOS||Disease||Thomas Lee, MD, PhD, University of California, Los Angeles|| || || || ||FQR|| ||
 
|Myeloproliferative neoplasm, NOS||Disease||Thomas Lee, MD, PhD, University of California, Los Angeles|| || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
Line 86: Line 98:  
|-
 
|-
 
|Cutaneous mastocytosis||Disease||S. Shawn Liu, MD, PhD and Thuy Phung, MD, PhD|| || || || ||FQR|| ||
 
|Cutaneous mastocytosis||Disease||S. Shawn Liu, MD, PhD and Thuy Phung, MD, PhD|| || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
Line 92: Line 105:  
|-
 
|-
 
|Systemic mastocytosis||Disease||'''Abdullah Osme, MD,''' University Hospitals Cleveland Medical Center, Case Western Reserve University  '''Shashi Shetty, Ph.D. FACMG, FCCMG,''' University Hospitals Cleveland Medical Center, Case Western Reserve University|| || || || ||FQR|| ||
 
|Systemic mastocytosis||Disease||'''Abdullah Osme, MD,''' University Hospitals Cleveland Medical Center, Case Western Reserve University  '''Shashi Shetty, Ph.D. FACMG, FCCMG,''' University Hospitals Cleveland Medical Center, Case Western Reserve University|| || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
Line 98: Line 112:  
|-
 
|-
 
|Mast cell sarcoma||Disease||Jordan Lowery, MD and Thuy Phung, MD, PhD  Department of Pathology, University of South Alabama, Mobile, AL|| || || || ||FQR|| ||
 
|Mast cell sarcoma||Disease||Jordan Lowery, MD and Thuy Phung, MD, PhD  Department of Pathology, University of South Alabama, Mobile, AL|| || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
Line 104: Line 119:  
|-
 
|-
 
|Myelodysplastic neoplasm with low blasts and 5q deletion||Disease|| || || || || ||FQR|| ||
 
|Myelodysplastic neoplasm with low blasts and 5q deletion||Disease|| || || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
Line 110: Line 126:  
|-
 
|-
 
|Myelodysplastic neoplasm with low blasts and SF3B1 mutation||Disease|| || || || || ||FQR|| ||
 
|Myelodysplastic neoplasm with low blasts and SF3B1 mutation||Disease|| || || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
Line 116: Line 133:  
|-
 
|-
 
|Myelodysplastic neoplasm with biallelic TP53 inactivation||Disease|| || || || || ||FQR|| ||
 
|Myelodysplastic neoplasm with biallelic TP53 inactivation||Disease|| || || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
Line 122: Line 140:  
|-
 
|-
 
|Myelodysplastic neoplasm with low blasts||Disease|| || || || || ||FQR|| ||
 
|Myelodysplastic neoplasm with low blasts||Disease|| || || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
Line 128: Line 147:  
|-
 
|-
 
|Myelodysplastic neoplasm, hypoplastic||Disease|| || || || || ||FQR|| ||
 
|Myelodysplastic neoplasm, hypoplastic||Disease|| || || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
Line 134: Line 154:  
|-
 
|-
 
|Myelodysplastic neoplasm with increased blasts||Disease||Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.|| || || || ||FQR|| ||
 
|Myelodysplastic neoplasm with increased blasts||Disease||Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.|| || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
Line 140: Line 161:  
|-
 
|-
 
|Childhood myelodysplastic neoplasm with low blasts||Disease||Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.|| || || || ||FQR|| ||
 
|Childhood myelodysplastic neoplasm with low blasts||Disease||Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.|| || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
Line 146: Line 168:  
|-
 
|-
 
|Childhood myelodysplastic neoplasm with increased blasts||Disease||Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.|| || || || ||FQR|| ||
 
|Childhood myelodysplastic neoplasm with increased blasts||Disease||Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.|| || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
Line 152: Line 175:  
|-
 
|-
 
|Chronic myelomonocytic leukaemia||Disease||Linsheng Zhang, MD, PhD|| || || || ||FQR|| ||
 
|Chronic myelomonocytic leukaemia||Disease||Linsheng Zhang, MD, PhD|| || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
Line 158: Line 182:  
|-
 
|-
 
|Myelodysplastic/myeloproliferative neoplasm with neutrophilia||Disease||Linsheng Zhang, MD, PhD|| || || || ||FQR|| ||
 
|Myelodysplastic/myeloproliferative neoplasm with neutrophilia||Disease||Linsheng Zhang, MD, PhD|| || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
Line 164: Line 189:  
|-
 
|-
 
|Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis||Disease||Anamaria Munteanu, MD, Ph.D, Harbor-UCLA Medical Center, Fabiola Quintero-Rivera, University of California Irvine|| || || || ||FQR|| ||
 
|Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis||Disease||Anamaria Munteanu, MD, Ph.D, Harbor-UCLA Medical Center, Fabiola Quintero-Rivera, University of California Irvine|| || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
Line 170: Line 196:  
|-
 
|-
 
|Myelodysplastic/myeloproliferative neoplasm, NOS||Disease||Ruth MacKinnon PhD  Victorian Cancer Cytogenetics Service  Melbourne, Australia|| || || || ||FQR|| ||
 
|Myelodysplastic/myeloproliferative neoplasm, NOS||Disease||Ruth MacKinnon PhD  Victorian Cancer Cytogenetics Service  Melbourne, Australia|| || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
Line 176: Line 203:  
|-
 
|-
 
|Myeloid/lymphoid neoplasm with PDGFRA rearrangement||Disease||Jay Alden, DO|| || || || ||FQR|| ||
 
|Myeloid/lymphoid neoplasm with PDGFRA rearrangement||Disease||Jay Alden, DO|| || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
Line 182: Line 210:  
|-
 
|-
 
|Myeloid/lymphoid neoplasm with PDGFRB rearrangement||Disease||Christopher Sullivan, MD, MPH and Daynna J. Wolff, PhD|| || || || ||FQR|| ||
 
|Myeloid/lymphoid neoplasm with PDGFRB rearrangement||Disease||Christopher Sullivan, MD, MPH and Daynna J. Wolff, PhD|| || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
Line 188: Line 217:  
|-
 
|-
 
|Myeloid/lymphoid neoplasm with FGFR1 rearrangement||Disease||Yanna Ding, MD PhD|| || || || ||FQR|| ||
 
|Myeloid/lymphoid neoplasm with FGFR1 rearrangement||Disease||Yanna Ding, MD PhD|| || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
Line 194: Line 224:  
|-
 
|-
 
|Myeloid/lymphoid neoplasm with JAK2 rearrangement||Disease||Jessica Snider, M.D. and Daynna J. Wolff, PhD|| || || || ||FQR|| ||
 
|Myeloid/lymphoid neoplasm with JAK2 rearrangement||Disease||Jessica Snider, M.D. and Daynna J. Wolff, PhD|| || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
Line 200: Line 231:  
|-
 
|-
 
|Myeloid/lymphoid neoplasm with FLT3 rearrangement||Disease|| || || || || ||FQR|| ||
 
|Myeloid/lymphoid neoplasm with FLT3 rearrangement||Disease|| || || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
Line 206: Line 238:  
|-
 
|-
 
|Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion||Disease|| || || || || ||FQR|| ||
 
|Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion||Disease|| || || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
Line 212: Line 245:  
|-
 
|-
 
|Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes||Disease|| || || || || ||FQR|| ||
 
|Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes||Disease|| || || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
Line 225: Line 259:  
|
 
|
 
|Jennelle Hodge (JH)/ Malini Sathanoori (MS)
 
|Jennelle Hodge (JH)/ Malini Sathanoori (MS)
 +
|
 
|
 
|
 
|
 
|
Line 240: Line 275:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 255: Line 291:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 270: Line 307:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 285: Line 323:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 300: Line 339:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 315: Line 355:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 330: Line 371:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 345: Line 387:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 360: Line 403:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 375: Line 419:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 390: Line 435:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 405: Line 451:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 420: Line 467:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 435: Line 483:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 450: Line 499:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 465: Line 515:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 480: Line 531:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 495: Line 547:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 510: Line 563:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 525: Line 579:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 540: Line 595:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 555: Line 611:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 570: Line 627:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 585: Line 643:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 600: Line 659:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 615: Line 675:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 630: Line 691:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 645: Line 707:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 660: Line 723:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 675: Line 739:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 690: Line 755:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 705: Line 771:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 717: Line 784:  
|
 
|
 
----<br />
 
----<br />
 +
|
 
|
 
|
 
|
 
|
Line 737: Line 805:  
|
 
|
 
|Greg Corboy (GC)
 
|Greg Corboy (GC)
 +
|
 
|
 
|
 
|
 
|
Line 752: Line 821:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 767: Line 837:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 782: Line 853:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 797: Line 869:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 812: Line 885:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 827: Line 901:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 842: Line 917:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 857: Line 933:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 872: Line 949:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 887: Line 965:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 899: Line 978:  
|
 
|
 
----<br />
 
----<br />
 +
|
 
|
 
|
 
|
 
|
Line 919: Line 999:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 934: Line 1,015:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 949: Line 1,031:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 964: Line 1,047:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 979: Line 1,063:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 994: Line 1,079:  
|
 
|
 
|Holli Drendel (HD)
 
|Holli Drendel (HD)
 +
|
 
|
 
|
 
|
 
|
Line 1,009: Line 1,095:  
|
 
|
 
|HD
 
|HD
 +
|
 
|
 
|
 
|
 
|
Line 1,024: Line 1,111:  
|
 
|
 
|HD
 
|HD
 +
|
 
|
 
|
 
|
 
|
Line 1,039: Line 1,127:  
|
 
|
 
|HD
 
|HD
 +
|
 
|
 
|
 
|
 
|
Line 1,054: Line 1,143:  
|
 
|
 
|HD
 
|HD
 +
|
 
|
 
|
 
|
 
|
Line 1,069: Line 1,159:  
|
 
|
 
|HD
 
|HD
 +
|
 
|
 
|
 
|
 
|
Line 1,084: Line 1,175:  
|
 
|
 
|HD
 
|HD
 +
|
 
|
 
|
 
|
 
|
Line 1,099: Line 1,191:  
|
 
|
 
|HD
 
|HD
 +
|
 
|
 
|
 
|
 
|
Line 1,114: Line 1,207:  
|
 
|
 
|HD
 
|HD
 +
|
 
|
 
|
 
|
 
|
Line 1,129: Line 1,223:  
|
 
|
 
|HD
 
|HD
 +
|
 
|
 
|
 
|
 
|
Line 1,144: Line 1,239:  
|
 
|
 
|HD
 
|HD
 +
|
 
|
 
|
 
|
 
|
Line 1,159: Line 1,255:  
|
 
|
 
|HD
 
|HD
 +
|
 
|
 
|
 
|
 
|
Line 1,174: Line 1,271:  
|
 
|
 
|HD
 
|HD
 +
|
 
|
 
|
 
|
 
|
Line 1,189: Line 1,287:  
|
 
|
 
|HD
 
|HD
 +
|
 
|
 
|
 
|
 
|
Line 1,198: Line 1,297:  
|Monoclonal B-cell lymphocytosis||Disease|| || || || || ||Shivani Golem (SG)
 
|Monoclonal B-cell lymphocytosis||Disease|| || || || || ||Shivani Golem (SG)
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,204: Line 1,304:  
|-
 
|-
 
|Chronic lymphocytic leukaemia/small lymphocytic lymphoma||Disease||Jamie Nagy, PhD, University of Iowa  Honey Reddi, PhD|| || || || ||SG|| ||
 
|Chronic lymphocytic leukaemia/small lymphocytic lymphoma||Disease||Jamie Nagy, PhD, University of Iowa  Honey Reddi, PhD|| || || || ||SG|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,210: Line 1,311:  
|-
 
|-
 
|Hairy cell leukaemia||Disease||*Snehal Patel, MD, PhD|| || || || ||SG|| ||
 
|Hairy cell leukaemia||Disease||*Snehal Patel, MD, PhD|| || || || ||SG|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,216: Line 1,318:  
|-
 
|-
 
|Splenic marginal zone lymphoma||Disease||*Snehal Patel, MD, PhD|| || || || ||SG|| ||
 
|Splenic marginal zone lymphoma||Disease||*Snehal Patel, MD, PhD|| || || || ||SG|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,222: Line 1,325:  
|-
 
|-
 
|Splenic diffuse red pulp small B-cell lymphoma||Disease||*Snehal Patel, MD, PhD|| || || || ||SG|| ||
 
|Splenic diffuse red pulp small B-cell lymphoma||Disease||*Snehal Patel, MD, PhD|| || || || ||SG|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,235: Line 1,339:  
|
 
|
 
|SG
 
|SG
 +
|
 
|
 
|
 
|
 
|
Line 1,250: Line 1,355:  
|
 
|
 
|SG
 
|SG
 +
|
 
|
 
|
 
|
 
|
Line 1,265: Line 1,371:  
|
 
|
 
|SG
 
|SG
 +
|
 
|
 
|
 
|
 
|
Line 1,280: Line 1,387:  
|
 
|
 
|SG
 
|SG
 +
|
 
|
 
|
 
|
 
|
Line 1,295: Line 1,403:  
|
 
|
 
|SG
 
|SG
 +
|
 
|
 
|
 
|
 
|
Line 1,310: Line 1,419:  
|
 
|
 
|SG
 
|SG
 +
|
 
|
 
|
 
|
 
|
Line 1,325: Line 1,435:  
|
 
|
 
|SG
 
|SG
 +
|
 
|
 
|
 
|
 
|
Line 1,340: Line 1,451:  
|
 
|
 
|SG
 
|SG
 +
|
 
|
 
|
 
|
 
|
Line 1,355: Line 1,467:  
|
 
|
 
|SG
 
|SG
 +
|
 
|
 
|
 
|
 
|
Line 1,370: Line 1,483:  
|
 
|
 
|SG
 
|SG
 +
|
 
|
 
|
 
|
 
|
Line 1,385: Line 1,499:  
|
 
|
 
|SG
 
|SG
 +
|
 
|
 
|
 
|
 
|
Line 1,400: Line 1,515:  
|
 
|
 
|SG
 
|SG
 +
|
 
|
 
|
 
|
 
|
Line 1,415: Line 1,531:  
|
 
|
 
|SG
 
|SG
 +
|
 
|
 
|
 
|
 
|
Line 1,430: Line 1,547:  
|
 
|
 
|SG
 
|SG
 +
|
 
|
 
|
 
|
 
|
Line 1,445: Line 1,563:  
|
 
|
 
|SG
 
|SG
 +
|
 
|
 
|
 
|
 
|
Line 1,453: Line 1,572:  
|-
 
|-
 
|Diffuse large B-cell lymphoma, NOS||Disease||Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center|| || || || ||GC|| ||
 
|Diffuse large B-cell lymphoma, NOS||Disease||Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center|| || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,459: Line 1,579:  
|-
 
|-
 
|T-cell/histiocyte-rich large B-cell lymphoma||Disease|| || || || || ||GC|| ||
 
|T-cell/histiocyte-rich large B-cell lymphoma||Disease|| || || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,465: Line 1,586:  
|-
 
|-
 
|Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements||Disease||Kate Berry, MBBS, BBus (Hons), Pathology Queensland|| || || || ||GC|| ||
 
|Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements||Disease||Kate Berry, MBBS, BBus (Hons), Pathology Queensland|| || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,471: Line 1,593:  
|-
 
|-
 
|ALK-positive large B-cell lymphoma||Disease||Manando Nakasaki, MD, PhD (University of California, Irvine)  Fabiola Quintero-Rivera, MD, FACMG (University of California, Irvine)|| || || || ||GC|| ||
 
|ALK-positive large B-cell lymphoma||Disease||Manando Nakasaki, MD, PhD (University of California, Irvine)  Fabiola Quintero-Rivera, MD, FACMG (University of California, Irvine)|| || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,477: Line 1,600:  
|-
 
|-
 
|Large B-cell lymphoma with IRF4 rearrangement||Disease||*Afia Hasnain, MBBS, PhD|| || || || ||GC|| ||
 
|Large B-cell lymphoma with IRF4 rearrangement||Disease||*Afia Hasnain, MBBS, PhD|| || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,483: Line 1,607:  
|-
 
|-
 
|High grade B-cell lymphoma with 11q aberrations||Disease||Lauren Shealy, MD, Medical University of South Carolina  Daynna Wolff, PhD, Medical University of South Carolina|| || || || ||GC|| ||
 
|High grade B-cell lymphoma with 11q aberrations||Disease||Lauren Shealy, MD, Medical University of South Carolina  Daynna Wolff, PhD, Medical University of South Carolina|| || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,489: Line 1,614:  
|-
 
|-
 
|Lymphomatoid granulomatosis||Disease|| || || || || ||GC|| ||
 
|Lymphomatoid granulomatosis||Disease|| || || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,495: Line 1,621:  
|-
 
|-
 
|EBV-positive diffuse large B-cell lymphoma||Disease|| || || || || ||GC|| ||
 
|EBV-positive diffuse large B-cell lymphoma||Disease|| || || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,501: Line 1,628:  
|-
 
|-
 
|Diffuse large B-cell lymphoma associated with chronic inflammation||Disease|| || || || || ||GC|| ||
 
|Diffuse large B-cell lymphoma associated with chronic inflammation||Disease|| || || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,507: Line 1,635:  
|-
 
|-
 
|Fibrin-associated large B-cell lymphoma||Disease|| || || || || ||GC|| ||
 
|Fibrin-associated large B-cell lymphoma||Disease|| || || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,513: Line 1,642:  
|-
 
|-
 
|Fluid overload-associated large B-cell lymphoma||Disease|| || || || || ||GC|| ||
 
|Fluid overload-associated large B-cell lymphoma||Disease|| || || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,519: Line 1,649:  
|-
 
|-
 
|Plasmablastic lymphoma||Disease||Mark Evans, MD (University of California, Irvine)  Fabiola Quintero-Rivera, MD (University of California, Irvine)|| || || || ||GC|| ||
 
|Plasmablastic lymphoma||Disease||Mark Evans, MD (University of California, Irvine)  Fabiola Quintero-Rivera, MD (University of California, Irvine)|| || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,525: Line 1,656:  
|-
 
|-
 
|Primary large B-cell lymphoma of immune-privileged sites||Disease||Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center|| || || || ||GC|| ||
 
|Primary large B-cell lymphoma of immune-privileged sites||Disease||Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center|| || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,531: Line 1,663:  
|-
 
|-
 
|Primary cutaneous diffuse large B-cell lymphoma, leg type||Disease|| || || || || ||GC|| ||
 
|Primary cutaneous diffuse large B-cell lymphoma, leg type||Disease|| || || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,537: Line 1,670:  
|-
 
|-
 
|Intravascular large B-cell lymphoma||Disease||Kate Berry, MBBS, BBus (Hons), Pathology Queensland|| || || || ||GC|| ||
 
|Intravascular large B-cell lymphoma||Disease||Kate Berry, MBBS, BBus (Hons), Pathology Queensland|| || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,543: Line 1,677:  
|-
 
|-
 
|Primary mediastinal large B-cell lymphoma||Disease|| || || || || ||GC|| ||
 
|Primary mediastinal large B-cell lymphoma||Disease|| || || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,549: Line 1,684:  
|-
 
|-
 
|Mediastinal grey zone lymphoma||Disease|| || || || || ||GC|| ||
 
|Mediastinal grey zone lymphoma||Disease|| || || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,555: Line 1,691:  
|-
 
|-
 
|High-grade B-cell lymphoma, NOS||Disease||Aiko Otsubo, PhD, Indiana University|| || || || ||GC|| ||
 
|High-grade B-cell lymphoma, NOS||Disease||Aiko Otsubo, PhD, Indiana University|| || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,561: Line 1,698:  
|-
 
|-
 
|Burkitt lymphoma||Disease||Becky Leung, MBBS (Hons), BSc, Pathology Queensland|| || || || ||GC|| ||
 
|Burkitt lymphoma||Disease||Becky Leung, MBBS (Hons), BSc, Pathology Queensland|| || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,567: Line 1,705:  
|-
 
|-
 
|Primary effusion lymphoma||Disease|| || || || || ||GC|| ||
 
|Primary effusion lymphoma||Disease|| || || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,573: Line 1,712:  
|-
 
|-
 
|KSHV/HHV8-positive diffuse large B-cell lymphoma||Disease|| || || || || ||GC|| ||
 
|KSHV/HHV8-positive diffuse large B-cell lymphoma||Disease|| || || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,579: Line 1,719:  
|-
 
|-
 
|KSHV/HHV8-positive germinotropic lymphoproliferative disorder||Disease|| || || || || ||GC|| ||
 
|KSHV/HHV8-positive germinotropic lymphoproliferative disorder||Disease|| || || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,585: Line 1,726:  
|-
 
|-
 
|Hyperplasias arising in immune deficiency/dysregulation||Disease|| || || || || ||GC|| ||
 
|Hyperplasias arising in immune deficiency/dysregulation||Disease|| || || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,591: Line 1,733:  
|-
 
|-
 
|Polymorphic lymphoproliferative disorders arising in immune deficiency / dysregulation||Disease||Anna Shestakova, MD, PhD, Fellow, University of Utah/ARUP Laboratories  Fabiola Quintero-Rivera, MD, Professor, University of California Irvine (UCI)|| || || || ||GC|| ||
 
|Polymorphic lymphoproliferative disorders arising in immune deficiency / dysregulation||Disease||Anna Shestakova, MD, PhD, Fellow, University of Utah/ARUP Laboratories  Fabiola Quintero-Rivera, MD, Professor, University of California Irvine (UCI)|| || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,597: Line 1,740:  
|-
 
|-
 
|EBV-positive mucocutaneous ulcer||Disease|| || || || || ||GC|| ||
 
|EBV-positive mucocutaneous ulcer||Disease|| || || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,603: Line 1,747:  
|-
 
|-
 
|Lymphomas arising in immune deficiency / dysregulation||Disease|| || || || || ||GC|| ||
 
|Lymphomas arising in immune deficiency / dysregulation||Disease|| || || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,609: Line 1,754:  
|-
 
|-
 
|Inborn error of immunity-associated lymphoid proliferations and lymphomas||Disease|| || || || || ||GC|| ||
 
|Inborn error of immunity-associated lymphoid proliferations and lymphomas||Disease|| || || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,615: Line 1,761:  
|-
 
|-
 
|Classic Hodgkin lymphoma||Disease||Patricia V. Hernandez, M.D., Washington University School of Medicine|| || || || ||GC|| ||
 
|Classic Hodgkin lymphoma||Disease||Patricia V. Hernandez, M.D., Washington University School of Medicine|| || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,621: Line 1,768:  
|-
 
|-
 
|Nodular lymphocyte predominant Hodgkin lymphoma||Disease|| || || || || ||GC|| ||
 
|Nodular lymphocyte predominant Hodgkin lymphoma||Disease|| || || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,634: Line 1,782:  
|
 
|
 
|SG
 
|SG
 +
|
 
|
 
|
 
|
 
|
Line 1,642: Line 1,791:  
|-
 
|-
 
|IgM monoclonal gammopathy of undetermined significance||Disease|| || || || || ||SG|| ||
 
|IgM monoclonal gammopathy of undetermined significance||Disease|| || || || || ||SG|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,648: Line 1,798:  
|-
 
|-
 
|Non-IgM monoclonal gammopathy of undetermined significance||Disease|| || || || || ||SG|| ||
 
|Non-IgM monoclonal gammopathy of undetermined significance||Disease|| || || || || ||SG|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,655: Line 1,806:  
|Monoclonal gammopathy of renal significance||Disease|| || || || || ||SG
 
|Monoclonal gammopathy of renal significance||Disease|| || || || || ||SG
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,662: Line 1,814:  
|Immunoglobulin-related (AL) amyloidosis||Disease||Heather E. Williams, PhD, MS, PgD, ErCLG|| || || || ||SG
 
|Immunoglobulin-related (AL) amyloidosis||Disease||Heather E. Williams, PhD, MS, PgD, ErCLG|| || || || ||SG
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,669: Line 1,822:  
|Monoclonal immunoglobulin deposition disease||Disease||Chen Yang, MD, PhD, University of Michigan|| || || || ||SG
 
|Monoclonal immunoglobulin deposition disease||Disease||Chen Yang, MD, PhD, University of Michigan|| || || || ||SG
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,676: Line 1,830:  
|Mu heavy chain disease||Disease|| || || || || ||SG
 
|Mu heavy chain disease||Disease|| || || || || ||SG
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,683: Line 1,838:  
|Gamma heavy chain disease||Disease||Manisha Brahmbhatt-Sutariya  Asst. Professor, Dept. of Pathology and Human Anatomy  Technical Supervisor, Clinical Genetics Laboratory  Loma Linda University, Medical Center, CA|| || || || ||SG
 
|Gamma heavy chain disease||Disease||Manisha Brahmbhatt-Sutariya  Asst. Professor, Dept. of Pathology and Human Anatomy  Technical Supervisor, Clinical Genetics Laboratory  Loma Linda University, Medical Center, CA|| || || || ||SG
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,690: Line 1,846:  
|Alpha heavy chain disease||Disease|| || || || || ||SG
 
|Alpha heavy chain disease||Disease|| || || || || ||SG
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,697: Line 1,854:  
|Plasmacytoma||Disease|| || || || || ||SG
 
|Plasmacytoma||Disease|| || || || || ||SG
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,704: Line 1,862:  
|Plasma cell myeloma / multiple myeloma||Disease||*Huan Mo, MD, MS *Zhenya Tang, MD, PhD  The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas|| || || || ||SG
 
|Plasma cell myeloma / multiple myeloma||Disease||*Huan Mo, MD, MS *Zhenya Tang, MD, PhD  The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas|| || || || ||SG
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,711: Line 1,870:  
|Plasma cell neoplasms with associated paraneoplastic syndrome||Disease||Sohini Anand, MBBS  Tharanga Niroshini Senaratne, PhD|| || || || ||SG
 
|Plasma cell neoplasms with associated paraneoplastic syndrome||Disease||Sohini Anand, MBBS  Tharanga Niroshini Senaratne, PhD|| || || || ||SG
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,721: Line 1,881:  
|
 
|
 
----<br />
 
----<br />
 +
|
 
|
 
|
 
|
 
|
Line 1,735: Line 1,896:  
|Kikuchi-Fujimoto disease||Disease|| || || || || ||Sumi Kitahara (SK)
 
|Kikuchi-Fujimoto disease||Disease|| || || || || ||Sumi Kitahara (SK)
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,741: Line 1,903:  
|-
 
|-
 
|Autoimmune lymphoproliferative syndrome||Disease|| || || || || ||SK|| ||
 
|Autoimmune lymphoproliferative syndrome||Disease|| || || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,747: Line 1,910:  
|-
 
|-
 
|Indolent T-lymphoblastic proliferation||Disease|| || || || || ||SK|| ||
 
|Indolent T-lymphoblastic proliferation||Disease|| || || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,753: Line 1,917:  
|-
 
|-
 
|T-lymphoblastic leukaemia / lymphoma, NOS||Disease|| || || || || ||HD|| ||
 
|T-lymphoblastic leukaemia / lymphoma, NOS||Disease|| || || || || ||HD|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,766: Line 1,931:  
|
 
|
 
|HD
 
|HD
 +
|
 
|
 
|
 
|
 
|
Line 1,781: Line 1,947:  
|
 
|
 
|SK
 
|SK
 +
|
 
|
 
|
 
|
 
|
Line 1,789: Line 1,956:  
|-
 
|-
 
|T-large granular lymphocytic leukaemia||Disease||*Michelle Don, MD, MS|| || || || ||SK|| ||
 
|T-large granular lymphocytic leukaemia||Disease||*Michelle Don, MD, MS|| || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,795: Line 1,963:  
|-
 
|-
 
|NK-large granular lymphocytic leukaemia||Disease||Michelle Don, MD|| || || || ||SK|| ||
 
|NK-large granular lymphocytic leukaemia||Disease||Michelle Don, MD|| || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,801: Line 1,970:  
|-
 
|-
 
|Adult T-cell leukaemia/lymphoma||Disease||Prasad R. Kopparapu, PhD and Ferrin C. Wheeler, PhD, FACMG  Vanderbilt University Medical Center|| || || || ||SK|| ||
 
|Adult T-cell leukaemia/lymphoma||Disease||Prasad R. Kopparapu, PhD and Ferrin C. Wheeler, PhD, FACMG  Vanderbilt University Medical Center|| || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,807: Line 1,977:  
|-
 
|-
 
|Sezary syndrome||Disease||Madison E. Hannay, DO, Medical University of South Carolina  Tingting Barrett, MD, Medical University of South Carolina  Daynna J. Wolff, PhD, Medical University of South Carolina|| || || || ||SK|| ||
 
|Sezary syndrome||Disease||Madison E. Hannay, DO, Medical University of South Carolina  Tingting Barrett, MD, Medical University of South Carolina  Daynna J. Wolff, PhD, Medical University of South Carolina|| || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,813: Line 1,984:  
|-
 
|-
 
|Aggressive NK-cell leukaemia||Disease||Shanelle De Lancy, MD, Shashirekha Shetty, PhD|| || || || ||SK|| ||
 
|Aggressive NK-cell leukaemia||Disease||Shanelle De Lancy, MD, Shashirekha Shetty, PhD|| || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,819: Line 1,991:  
|-
 
|-
 
|Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder||Disease|| || || || || ||SK|| ||
 
|Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder||Disease|| || || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,825: Line 1,998:  
|-
 
|-
 
|Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder||Disease|| || || || || ||SK|| ||
 
|Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder||Disease|| || || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,831: Line 2,005:  
|-
 
|-
 
|Mycosis fungoides||Disease||Jane Scribner, MD and Daynna J. Wolff, PhD|| || || || ||SK|| ||
 
|Mycosis fungoides||Disease||Jane Scribner, MD and Daynna J. Wolff, PhD|| || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,837: Line 2,012:  
|-
 
|-
 
|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis||Disease|| || || || || ||SK|| ||
 
|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis||Disease|| || || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,843: Line 2,019:  
|-
 
|-
 
|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma||Disease||Theresa Spivey, MD, Shashirekha Shetty, PhD|| || || || ||SK|| ||
 
|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma||Disease||Theresa Spivey, MD, Shashirekha Shetty, PhD|| || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,849: Line 2,026:  
|-
 
|-
 
|Subcutaneous panniculitis-like T-cell lymphoma||Disease|| || || || || ||SK|| ||
 
|Subcutaneous panniculitis-like T-cell lymphoma||Disease|| || || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,855: Line 2,033:  
|-
 
|-
 
|Primary cutaneous gamma/delta T-cell lymphoma||Disease|| || || || || ||SK|| ||
 
|Primary cutaneous gamma/delta T-cell lymphoma||Disease|| || || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,861: Line 2,040:  
|-
 
|-
 
|Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma||Disease|| || || || || ||SK|| ||
 
|Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma||Disease|| || || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,867: Line 2,047:  
|-
 
|-
 
|Primary cutaneous peripheral T-cell lymphoma, NOS||Disease|| || || || || ||SK|| ||
 
|Primary cutaneous peripheral T-cell lymphoma, NOS||Disease|| || || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,873: Line 2,054:  
|-
 
|-
 
|Indolent T-cell lymphoma of the gastrointestinal tract||Disease||Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD|| || || || ||SK|| ||
 
|Indolent T-cell lymphoma of the gastrointestinal tract||Disease||Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD|| || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,879: Line 2,061:  
|-
 
|-
 
|Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract||Disease|| || || || || ||SK|| ||
 
|Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract||Disease|| || || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,885: Line 2,068:  
|-
 
|-
 
|Enteropathy-associated T-cell lymphoma||Disease||*Derick Okwan-Duodu, MD, PhD *Sumire Kitahara, MD|| || || || ||SK|| ||
 
|Enteropathy-associated T-cell lymphoma||Disease||*Derick Okwan-Duodu, MD, PhD *Sumire Kitahara, MD|| || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,891: Line 2,075:  
|-
 
|-
 
|Monomorphic epitheliotropic intestinal T-cell lymphoma||Disease||Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD|| || || || ||SK|| ||
 
|Monomorphic epitheliotropic intestinal T-cell lymphoma||Disease||Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD|| || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,897: Line 2,082:  
|-
 
|-
 
|Intestinal T-cell lymphoma, NOS||Disease||Derick Okwan MD, PhD (Stanford Medicine, CA)  Sumire Kitahara MD (Cedars-Sinai, CA)|| || || || ||SK|| ||
 
|Intestinal T-cell lymphoma, NOS||Disease||Derick Okwan MD, PhD (Stanford Medicine, CA)  Sumire Kitahara MD (Cedars-Sinai, CA)|| || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,903: Line 2,089:  
|-
 
|-
 
|Hepatosplenic T-cell lymphoma||Disease||*Michelle Don, MD, MS|| || || || ||SK|| ||
 
|Hepatosplenic T-cell lymphoma||Disease||*Michelle Don, MD, MS|| || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,909: Line 2,096:  
|-
 
|-
 
|ALK-positive anaplastic large cell lymphoma||Disease|| || || || || ||SK|| ||
 
|ALK-positive anaplastic large cell lymphoma||Disease|| || || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,915: Line 2,103:  
|-
 
|-
 
|ALK-negative anaplastic large cell lymphoma||Disease||Miguel Gonzalez Mancera, MD  Sumire Kitahara, MD  Cedars-Sinai, Los Angeles, CA|| || || || ||SK|| ||
 
|ALK-negative anaplastic large cell lymphoma||Disease||Miguel Gonzalez Mancera, MD  Sumire Kitahara, MD  Cedars-Sinai, Los Angeles, CA|| || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,921: Line 2,110:  
|-
 
|-
 
|Breast implant-associated anaplastic large cell lymphoma||Disease||Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD  Cedars-Sinai Medical Center|| || || || ||SK|| ||
 
|Breast implant-associated anaplastic large cell lymphoma||Disease||Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD  Cedars-Sinai Medical Center|| || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,927: Line 2,117:  
|-
 
|-
 
|Nodal TFH cell lymphoma, angioimmunoblastic-type||Disease||* Sara Akhavanfard, M.D., Ph.D. * Ruthann Pfau, Ph.D., FACMG|| || || || ||SK|| ||
 
|Nodal TFH cell lymphoma, angioimmunoblastic-type||Disease||* Sara Akhavanfard, M.D., Ph.D. * Ruthann Pfau, Ph.D., FACMG|| || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,933: Line 2,124:  
|-
 
|-
 
|Nodal TFH cell lymphoma, follicular-type||Disease|| || || || || ||SK|| ||
 
|Nodal TFH cell lymphoma, follicular-type||Disease|| || || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,939: Line 2,131:  
|-
 
|-
 
|Nodal TFH cell lymphoma, NOS||Disease||Hans Magne Hamnvåg, MD  Kamran Mirza, MD, PhD|| || || || ||SK|| ||
 
|Nodal TFH cell lymphoma, NOS||Disease||Hans Magne Hamnvåg, MD  Kamran Mirza, MD, PhD|| || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,945: Line 2,138:  
|-
 
|-
 
|Peripheral T-cell lymphoma, NOS||Disease|| || || || || ||SK|| ||
 
|Peripheral T-cell lymphoma, NOS||Disease|| || || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,951: Line 2,145:  
|-
 
|-
 
|EBV-positive nodal T- and NK-cell lymphoma||Disease|| || || || || ||SK|| ||
 
|EBV-positive nodal T- and NK-cell lymphoma||Disease|| || || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,957: Line 2,152:  
|-
 
|-
 
|Extranodal NK/T-cell lymphoma||Disease|| || || || || ||SK|| ||
 
|Extranodal NK/T-cell lymphoma||Disease|| || || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,963: Line 2,159:  
|-
 
|-
 
|Severe mosquito bite allergy||Disease|| || || || || ||SK|| ||
 
|Severe mosquito bite allergy||Disease|| || || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,969: Line 2,166:  
|-
 
|-
 
|Hydroa vacciniforme lymphoproliferative disorder||Disease|| || || || || ||SK|| ||
 
|Hydroa vacciniforme lymphoproliferative disorder||Disease|| || || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,975: Line 2,173:  
|-
 
|-
 
|Systemic chronic active EBV disease||Disease|| || || || || ||SK|| ||
 
|Systemic chronic active EBV disease||Disease|| || || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,981: Line 2,180:  
|-
 
|-
 
|Systemic EBV-positive T-cell lymphoma of childhood||Disease||*Lisa A. Lansdon, PhD & Linda D. Cooley, MD, MBA|| || || || ||SK|| ||
 
|Systemic EBV-positive T-cell lymphoma of childhood||Disease||*Lisa A. Lansdon, PhD & Linda D. Cooley, MD, MBA|| || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,991: Line 2,191:  
|
 
|
 
----<br />
 
----<br />
 +
|
 
|
 
|
 
|
 
|
Line 2,011: Line 2,212:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 2,026: Line 2,228:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 2,041: Line 2,244:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 2,056: Line 2,260:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 2,071: Line 2,276:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 2,086: Line 2,292:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 2,101: Line 2,308:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 2,113: Line 2,321:  
|
 
|
 
----<br />
 
----<br />
 +
|
 
|
 
|
 
|
 
|
Line 2,126: Line 2,335:  
|-
 
|-
 
|Fanconi anaemia||Disease|| || || || || ||NA|| ||
 
|Fanconi anaemia||Disease|| || || || || ||NA|| ||
 +
|
 
|
 
|
 
|
 
|
Line 2,132: Line 2,342:  
|-
 
|-
 
|Bloom syndrome||Disease|| || || || || ||NA|| ||
 
|Bloom syndrome||Disease|| || || || || ||NA|| ||
 +
|
 
|
 
|
 
|
 
|
Line 2,138: Line 2,349:  
|-
 
|-
 
|Ataxia-telangiectasia syndrome||Disease|| || || || || ||NA|| ||
 
|Ataxia-telangiectasia syndrome||Disease|| || || || || ||NA|| ||
 +
|
 
|
 
|
 
|
 
|
Line 2,144: Line 2,356:  
|-
 
|-
 
|RASopathies||Disease|| || || || || ||NA|| ||
 
|RASopathies||Disease|| || || || || ||NA|| ||
 +
|
 
|
 
|
 
|
 
|
Retrieved from "https://content.ccga.io/index.php/Special:MobileDiff/13905"